Who are Spironolacton (hexalacton(R))'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Inspra, Aldactone, Phase C: Eplerenone, Eplerenone vs Amlodipine, Eplerenone (Morning), Aldactone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spironolacton-hexalacton-r.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Spironolacton (hexalacton(R)) — Competitive Intelligence Brief

Spironolacton (hexalacton(R)) (Spironolacton (hexalacton(R))) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium-sparing diuretic; aldosterone antagonist. Area: Cardiovascular.

marketed Potassium-sparing diuretic; aldosterone antagonist Mineralocorticoid receptor (MR) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Spironolacton (hexalacton(R)) (Spironolacton (hexalacton(R))) — Steno Diabetes Center Copenhagen. Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that blocks aldosterone receptors in the collecting duct of the kidney to reduce sodium reabsorption and increase potassium retention.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Spironolacton (hexalacton(R)) TARGET	Spironolacton (hexalacton(R))	Steno Diabetes Center Copenhagen	marketed	Potassium-sparing diuretic; aldosterone antagonist	Mineralocorticoid receptor (MR)
Inspra	EPLERENONE	Upjohn	marketed	Aldosterone Antagonist [EPC]	Mineralocorticoid receptor	2002-01-01
Aldactone	spironolactone	Generic (originally Searle/Pfizer)	marketed	Aldosterone Antagonist [EPC]	Cytochrome P450 2C19, Multidrug and toxin extrusion protein 1, Nuclear receptor subfamily 1 group I member 2	1960-01-01
Phase C: Eplerenone	Phase C: Eplerenone	National Institute of Cardiology, Warsaw, Poland	marketed	Selective aldosterone antagonist	Mineralocorticoid receptor (MR)
Eplerenone vs Amlodipine	Eplerenone vs Amlodipine	Brigham and Women's Hospital	marketed	Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine)	Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine)
Eplerenone (Morning)	Eplerenone (Morning)	Vanderbilt University Medical Center	marketed	Selective aldosterone antagonist	Mineralocorticoid receptor (MR)
Aldactone	Spironolactone	Pfizer Inc.	marketed	Potassium-sparing diuretic, aldosterone antagonist	Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2036-10-28 — Aldactone · 9757394 · Formulation · US
2036-10-28 — Aldactone · 11395828 · Method of Use · US
2036-10-28 — Aldactone · 10888570 · Formulation · US
2036-10-28 — Aldactone · 11389461 · Formulation · US
2036-10-28 — Aldactone · 10660907 · Formulation · US
2036-10-28 — Aldactone · 10624906 · Formulation · US
2036-10-28 — Aldactone · 10493083 · Formulation · US
2036-10-28 — Aldactone · 11491166 · Formulation · US

Sponsor landscape (Potassium-sparing diuretic; aldosterone antagonist class)

Steno Diabetes Center Copenhagen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Spironolacton (hexalacton(R)) — Competitive Intelligence Brief. https://druglandscape.com/ci/spironolacton-hexalacton-r. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab